scholarly journals Management Of Oral Anticoagulation In Patients, Undergoing Elective Surgery Or Invasive Procedures

2020 ◽  
Vol 6 (1) ◽  
pp. 42
Author(s):  
Antoniya Kisheva ◽  
Aylin Hadjiveli
2017 ◽  
Vol 217 (2) ◽  
pp. 103-107 ◽  
Author(s):  
D. Sánchez Fuentes ◽  
M.A. Budiño Sánchez ◽  
M.P. López Sánchez

2010 ◽  
Vol 1 (3) ◽  
pp. 92-98
Author(s):  
Nadzeya Kuzniatsova ◽  
Gregory YH Lip

Antithrombotic drugs are prescribed more and more often in medical practice. With a progressively aging population, the proportion of patients having prothrombotic medical conditions such as coronary artery disease, atrial fibrillation, venous thrombosis and many others increases dramatically. Anticoagulants or antiplatelet agents save thousands of lives annually but also introduce concerns of increased risk of bleeding, especially in the settings of elective surgery or invasive procedures.


2010 ◽  
Vol 23 (4) ◽  
pp. 303-312 ◽  
Author(s):  
Michelle T. Martin ◽  
Ann M. Kuchta ◽  
Edith A. Nutescu

Updates in recent clinical guidelines have led to a change in the management of perioperative anticoagulation for patients on oral anticoagulant therapy. No standardized bridging consensus exists in the literature. The necessity for bridging therapy is determined based on careful consideration of the thrombosis risk versus the bleeding risk of the procedure. Risk stratification will aid the decision to bridge or not to bridge. Patients are bridged with agents with appropriate kinetics to allow for their elimination prior to the time of the procedure in order to decrease the risk of hemorrhage during invasive procedures. This intent of this article is to discuss perioperative bridging therapy and provide a practical guide for the clinician.


2013 ◽  
Vol 118 (6) ◽  
pp. 1466-1474 ◽  
Author(s):  
Jerrold H. Levy ◽  
David Faraoni ◽  
Jenna L. Spring ◽  
James D. Douketis ◽  
Charles M. Samama

Abstract Managing patients in the perioperative setting receiving novel oral anticoagulation agents for thromboprophylaxis or stroke prevention with atrial fibrillation is an important consideration for clinicians. The novel oral anticoagulation agents include direct Factor Xa inhibitors rivaroxaban and apixaban, and the direct thrombin inhibitor dabigatran. In elective surgery, discontinuing their use is important, but renal function must also be considered because elimination is highly dependent on renal elimination. If bleeding occurs in patients who have received these agents, common principles of bleeding management as with any anticoagulant (including the known principles for warfarin) should be considered. This review summarizes the available data regarding the management of bleeding with novel oral anticoagulation agents. Hemodialysis is a therapeutic option for dabigatran-related bleeding, while in vitro studies showed that prothrombin complex concentrates are reported to be useful for rivaroxaban-related bleeding. Additional clinical studies are needed to determine the best method for reversal of the novel oral anticoagulation agents when bleeding occurs.


2003 ◽  
Vol 31 (2) ◽  
pp. 145-154 ◽  
Author(s):  
S. A. Watts ◽  
N. M. Gibbs

With the appropriate use of preadmission clinics, “hospital in the home” programs, and alternatives to intravenous heparin, the majority of chronically anticoagulated patients can be managed as outpatients prior to elective surgery. The preoperative management depends on the original indication for long-term anticoagulation, the interval since the last thromboembolic event, and the extent and type of surgery planned. Only patients who are undergoing major surgery, and who have a high risk of recurrent thrombosis or embolism, require preoperative admission to hospital and conversion to an intravenous heparin regimen. Patients undergoing minor surgery may require no change to their oral anticoagulation. The remainder require cessation of oral anticoagulation and alternative thromboprophylaxis preoperatively, which can be achieved on an outpatient basis using low molecular weight heparin. Outpatient anticoagulation management requires a clear protocol that is understood and agreed to by all parties involved in the care of surgical patients perioperatively.


1999 ◽  
Vol 56 (9) ◽  
pp. 481-483
Author(s):  
Züger ◽  
Demarmels Biasiutti

Wir berichten über einen 76jährigen Patienten, welcher trotz gut eingestellter oraler Antikoagulation mit Phenprocoumon rezidivierende Thrombosen erlitt bei leichtgradiger chronischer disseminierter intravasaler Gerinnung. Die Abklärungen ergaben das Vorliegen eines Bronchus-Karzinoms (Non small cell cancer of the lung, NSCCL) mit hilären und mediastinalen Lymphknotenmetastasen. Aufgrund der Assoziation von rezidivierenden Thrombosen, aktivierter Gerinnung und Tumorleiden wurde die Diagnose eines Trousseau Syndroms gestellt. Basierend auf Fallberichten aus der Literatur wurde die Therapie auf intravenöses Heparin gewechselt, welches die thrombotische Koagulopathie stoppte. Aus praktischen Gründen erfolgte dann eine Umstellung der Therapie auf subcutanes niedermolekulares Heparin in therapeutischer Dosierung, welches während 6.5 Monaten ebenso effektiv war und eine Alternative zur etablierten Therapie mit unfraktioniertem Heparin bei Trousseau Syndrom darstellen dürfte.


Sign in / Sign up

Export Citation Format

Share Document